Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L. Casabé A, et al. Among authors: sorsaburu s. J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2. J Urol. 2014. PMID: 24096118 Clinical Trial.
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Büttner H, Viktrup L. Glina S, et al. Among authors: sorsaburu s. J Sex Med. 2015 Jan;12(1):129-38. doi: 10.1111/jsm.12714. Epub 2014 Oct 29. J Sex Med. 2015. PMID: 25353053 Clinical Trial.
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Roehrborn CG, Casabé A, Glina S, Sorsaburu S, Henneges C, Viktrup L. Roehrborn CG, et al. Among authors: sorsaburu s. Int J Urol. 2015 Jun;22(6):582-7. doi: 10.1111/iju.12741. Epub 2015 Mar 31. Int J Urol. 2015. PMID: 25827166 Clinical Trial.
Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction.
Rubio-Aurioles E, El-Meliegy A, Abdulwahed S, Henneges C, Sorsaburu S, Gurbuz S. Rubio-Aurioles E, et al. Among authors: sorsaburu s. Curr Med Res Opin. 2015 Feb;31(2):367-78. doi: 10.1185/03007995.2014.946125. Epub 2014 Jul 29. Curr Med Res Opin. 2015. PMID: 25068906
A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, Shane MA, Sorsaburu S. Montorsi F, et al. Among authors: sorsaburu s. J Sex Med. 2011 Sep;8(9):2617-24. doi: 10.1111/j.1743-6109.2011.02353.x. Epub 2011 Jun 27. J Sex Med. 2011. PMID: 21707928 Clinical Trial.
20 results